Adcoris BioPharma announced a poster presentation of the preliminary phase I (NCT06238401) results of ACR246, an innovative and potentially best in class antibody-drug conjugate (ADC) against 5T4 antigen, at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting, taking place from May 30 to June 3 in Chicago, USA.
Poster Presentation Details:
Title: A dose escalation and cohort expansion phase l/lla study of ACR246, an innovative 5T4- antibody drug conjugate, in patients with advanced solid tumors.
Poster Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Date and Time: Monday, June 2, 2025, at 1:30 PM-4:30 PM CDT
Abstract Number: TPS3166
Poster Board Number: 476b
Lead Authors: Panpan Zhang, MD and Lin Shen, MD of Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Early Drug Development Centre, Peking University Cancer Hospital & Institute, Beiling 100142. China
About ACR246
ACR246 is an innovative antibody-drug conjugate targeting 5T4 antigen with 8 payloads (DAR8) of a novel TOP1 inhibitor connected by a stable and tumor microenvironment (TME) cleavable tripeptide linker. 5T4 is an oncofetal antigen (also known as trophoblast glycoprotein, TPBG) that has high expression in many solid tumors including ovarian, esophageal, colorectal, breast, NSCLC, gastric, prostate, urothelial, soft tissue sarcoma, etc., but no or limited expression in normal adult tissues. The preclinical studies demonstrated that ACR246 was highly potent and significantly superior to a reference Dxd-5T4 ADC in many tumor CDX and PDX models. Preliminary dose escalation study results in patients with advanced solid tumors indicated that ACR246 was very promising with good tolerance, no DLT incidence, manageable adverse events and significant efficacy in suppressing tumor growth. ACR246 has the potential to be a first and best in class for treating multiple solid tumors.
About ACR246-101
An open-label, multicenter, dose-escalation and cohort-expansion Phase I/IIa clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, and efficacy of ACR246 in patients with advanced solid tumors (NCT06238401).
The clinical phase I dose escalation study is being conducted at 3 sites: Peking University affiliated Beijing Cancer Hospital (Beijing), Shandong First Medical University affiliated Cancer Hospital (Jinan, Shandong) and Zhejiang Cancer Hospital (Hangzhou, Zhejiang).
About Adcoris
Adcoris BioPharma is a clinical stage biopharmaceutical company focusing on developing the next generation antibody-drug conjugate (ADC) and antibody conjugate beyond cytotoxic payload (AXC) therapeutics to address the unmet needs in oncology and autoimmune disease. Our state-of-the-art proprietary technology platform is based on internally developed three pillars of ADC technologies: proprietary and highly active payloads (PHAP™); cleavable, flexible and stable linkers (CLEF™), multifunctional site-specific conjugation (MuSC™). We can accelerate the development of ADC and AXC from target to IND enabling within 15 months. We have built a robust product pipeline including first-in-class (FIC) and first-in-generation (FIG) ADC and AXC in various development stages, including one completed phase 1 clinical study one in phase 1 and several with IND-enabling. Adcoris will look to collaborate with industry partners to codevelop our many promising ADC candidates and deliver better and faster outcomes for patients.